
Eagle Pharmaceuticals EGRX
Quarterly report 2023-Q2
added 08-08-2023
Eagle Pharmaceuticals ROCE Ratio 2011-2026 | EGRX
Annual ROCE Ratio Eagle Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.66 | 1.57 | 17.72 | 10.11 | 23.36 | 33.89 | 29.77 | 2.83 | -56.67 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 34.66 | -56.67 | 10.8 |
Quarterly ROCE Ratio Eagle Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.1 | 13.94 | 32.71 | 27.22 | 17.64 | 22.27 | -1.91 | 6.37 | 20.15 | 16.6 | 12.45 | 14.07 | 4.39 | 7.55 | 12.18 | 20.34 | 33.17 | 28.13 | 22.78 | 18.82 | 21.3 | 24.48 | 41.3 | 54.18 | 48.39 | 54.12 | 35.28 | 17.9 | -1.74 | -20.0 | 2.83 | -22.01 | -43.14 | -44.6 | -79.75 | -49.49 | -10.12 | -0.87 | 5.3 | 5.3 | -1.43 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 54.18 | -79.75 | 9.35 |
ROCE Ratio of other stocks in the Drug manufacturers industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Cumberland Pharmaceuticals
CPIX
|
-5.51 | $ 5.87 | 6.53 % | $ 87.2 M | ||
|
Endo International plc
ENDP
|
7.34 | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
-73.94 | - | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
-340.37 | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-33.39 | - | -0.1 % | $ 2.03 B | ||
|
AcelRx Pharmaceuticals
ACRX
|
-79.15 | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
-207.12 | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
3101.1 | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
267.43 | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
121.85 | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
-4.18 | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
-1.59 | $ 2.74 | 0.37 % | $ 1.05 B | ||
|
Harrow Health
HROW
|
58.18 | $ 33.0 | 0.12 % | $ 1.21 B | ||
|
Athenex
ATNX
|
1076.15 | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-57.41 | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
-20.78 | - | - | $ 11.5 B | ||
|
Organogenesis Holdings
ORGO
|
14.89 | $ 2.66 | - | $ 337 M | ||
|
Pacira BioSciences
PCRX
|
-9.43 | $ 23.35 | -0.55 % | $ 1.08 B | ||
|
Bausch Health Companies
BHC
|
-327.26 | $ 5.47 | 0.37 % | $ 2 B | ||
|
Canopy Growth Corporation
CGC
|
-24.04 | $ 1.04 | -2.8 % | $ 112 M | ||
|
Tilray
TLRY
|
-41.31 | $ 5.29 | -3.11 % | $ 3.27 B | ||
|
Solid Biosciences
SLDB
|
-90.02 | $ 6.62 | 1.85 % | $ 579 M | ||
|
Aurora Cannabis
ACB
|
0.81 | $ 3.46 | -2.81 % | $ 190 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-84.11 | $ 1.1 | 3.77 % | $ 1.37 M | ||
|
Jupiter Wellness
JUPW
|
-116.71 | - | - | $ 33.6 M | ||
|
Lannett Company
LCI
|
70.21 | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
-11.66 | $ 1.12 | -0.88 % | $ 107 M | ||
|
Evolus
EOLS
|
141.36 | $ 6.09 | -5.58 % | $ 393 M | ||
|
Sundial Growers
SNDL
|
-68.48 | $ 1.45 | -1.36 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
19.15 | $ 8.45 | 0.96 % | $ 433 M | ||
|
Veru
VERU
|
-135.01 | $ 2.35 | 5.86 % | $ 34.4 M | ||
|
Neoleukin Therapeutics
NLTX
|
-39.01 | - | - | $ 193 M | ||
|
cbdMD
YCBD
|
-29.93 | $ 0.76 | -2.32 % | $ 3.06 M | ||
|
Assertio Holdings
ASRT
|
-22.92 | $ 23.44 | 0.3 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
32.97 | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
21.53 | - | - | $ 1.42 B | ||
|
PetIQ
PETQ
|
5.46 | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
-68.31 | $ 7.04 | -2.36 % | $ 278 M | ||
|
Recro Pharma
REPH
|
-6.09 | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
26.27 | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
-32.55 | $ 0.73 | 3.0 % | $ 36.5 M | ||
|
PLx Pharma
PLXP
|
-114.37 | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
-18.1 | $ 16.65 | 1.15 % | $ 19.4 B | ||
|
Zomedica Corp.
ZOM
|
-73.1 | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-76.25 | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
-12.68 | $ 0.79 | -2.06 % | $ 28.4 M | ||
|
Tricida
TCDA
|
-70162.39 | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
-14.24 | $ 0.76 | -0.29 % | $ 3.26 M | ||
|
TherapeuticsMD
TXMD
|
-16.33 | $ 2.12 | 0.47 % | $ 24.5 M |